MARKET

INO

INO

Inovio Pharmaceu
NASDAQ
1.050
-0.040
-3.67%
After Hours: 1.070 +0.02 +1.90% 19:59 04/09 EDT
OPEN
1.090
PREV CLOSE
1.090
HIGH
1.110
LOW
1.050
VOLUME
2.92M
TURNOVER
--
52 WEEK HIGH
2.979
52 WEEK LOW
1.050
MARKET CAP
85.67M
P/E (TTM)
-0.5796
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on Top Healthcare Stocks: Inovio Pharmaceuticals (INO), Elevance Health (ELV)
TipRanks · 14h ago
Inovio Pharmaceuticals Inc. Stock Slides 7.1%, Underperforms Peers
Dow Jones · 2d ago
Inovio announces annual shareholder meeting in virtual-only format
Reuters · 2d ago
INO Deadline Today: INO Investors with Losses in Excess of $100K Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR Newswire · 2d ago
What's Going On With Inovio Pharmaceuticals Stock On Tuesday?
Benzinga · 2d ago
Inovio Deadline Today: Rosen Law Firm Urges Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Barchart · 2d ago
INO CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals Investors of Securities Class Action Deadline on April 7, 2026
Barchart · 2d ago
Inovio: 'Hold' As Upcoming PDUFA For INO-3107 Is Major Inflection Point
Seeking Alpha · 3d ago
More
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.

Webull offers Inovio Pharmaceuticals Inc stock information, including NASDAQ: INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.